ABIGAIL MONYEI (HPM) received this year's Dr. Edgar and Lauraine Duncan Scholarship which helps provide support for resources such as books, fees, stipends, or travel.
VOX – In his first State of the Union address, Donald Trump abandoned his pledges to bring down the cost of America’s medicines. Lowering the out-of-pocket costs that normal people feel is worthwhile but that won’t bring down the gross costs of prescription drugs. “They’re just going to raise premiums, or try to offset it another way,” HPM’s WALID GELLAD said of insurance plans. “Someone’s gonna pay the price if the price doesn’t come down.”
THE COMMONWEALTH FUND - HPM'S ERIC ROBERTS examined changes in hospital and primary care utilization among fee-for-service Medicare beneficiaries in Maryland and control counties outside the state. The researchers aimed to pinpoint utilization changes linked solely to the global budget intervention and not related to prior trends. To this end, the authors compared utilization before Maryland launched the program and during the first two years of...
STAT - Congressional efforts to lower drug prices are at a standstill. Powerful health industry players disagree about how to move forward. Every group pushes it's own agenda and strategies, making it unlikely that crushing drug prices will change any time soon. "It is correct that one of the reasons patients are feeling such high prices is because they have to pay coinsurance and deductibles, says HPM's WALID GELLAD. "And it's true that pharma ...
CNBC - “The administration has not lived up to the hype I think people expected around drug prices,” said HPM’s WALID GELLAD of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh. “They’ve done a few things, but it hasn’t lived up to the hype.”
STAT - “The market has spoken,” said WALID GELLAD of HPM and Pitt’s Center for Pharmaceutical Policy and Prescribing. “The key issue for success and sustainability will be how the generic manufacturers and trade groups respond, and also how other hospital groups might respond. It’s a new world. Insurers become hospitals. Hospitals become pharmaceutical manufacturers. At some point, manufacturers will become insurers and providers.”
BALTIMORE SUN - “The takeaway so far may be that when hospitals change the way the health care delivery system works, you don’t necessarily get a broader transformation that people had hoped for,” said lead author, HPM’s ERIC ROBERTS. There may be several reasons, including that doctors are not yet widely provided incentives to participate in Maryland’s program.
PITTSBURGH CITY PAPER - There are a number of areas statistics are being used for actual changes on the ground. One example is related to the opioid crisis. HPM’s ZAN DODSON, a postdoctoral researcher with the Public Health Dynamics Laboratory, used data on the concentration of opioid-related arrests to see which areas could use more “clean needle exchanges, Narcan kits, and readily available medical aid.”
BECKER'S HOSPITAL REVIEW - HPM alumnus and faculty member DEREK C. ANGUS, director of the Clinical Research, Investigation and Systems Modeling of Acute Illness laboratory at Pitt’s School of Medicine, has developed an evidence-based approach for managing post-hospitalization sepsis. “We need to focus not only on saving the patient’s life, but on ensuring the patient will have the best possible quality of life after leaving the hospital.”
90.5 WESA - Health policy researcher LINDSAY SABIK said that more cancer screenings may be driving these results, but added “there’s also the possibility that people do have symptoms and they go to see their health care provider soon after the symptoms begin, instead of putting off care because of concerns of costs or an inability to get recommended treatment.” Her research should be considered as the country debates the future of the Medicaid an...
INMACULADA HERNANDEZ (HPM ‘16) is working on developing her own independent research program at Pitt's School of Pharmacy, which is built at the intersection of pharmaceutical health services and outcomes research, pharmacoepidemiology, pharmacoeconomics and pharmaceutical policy.
TRI LE (HPM '16) is currently a research analyst in the Quality Measurement and Health Policy program at RTI International. He is part of a team that develops, maintains, re-evaluates, and implements outcome, structural, process, and composite quality measures for the Long-Term Care Hospital (LTCH), Inpatient Rehabilitation Facility (IRF), Skilled Nursing Facility (SNFs), and nursing home post-acute care quality programs.
CARROLINE LOBO (HPM '17) joined Cepheid, a bio-molecular diagnostics company located in the heart of Silicon Valley, in December 2017. Carroline reports to the vice president of Cepheid’s Government Affairs division, providing expert analytical support to guide reimbursement and market access related decisions.
ANA PROGOVAC (HPM '15) is currently an instructor of psychiatry at Harvard Medical School and senior scientist at the Health Equity Research Lab at Cambridge Health Alliance, which is a health system in Massachusetts serving Cambridge, Somerville, and Boston's Metro North Region.
MANIK RAZDAN (HPM '14) is currently working at Caring Health Center, Springfield, Massachusetts as a public health dentist. His work entails delivering dental care and oral health education to the underserved including people with limited financial means, African Americans, Hispanics and refugees. Manik also supervises fourth year dental students from Boston University during their externship rotations at the health center.